探讨聚乙二醇干扰素α-2a注射液联合利巴韦林治疗慢性丙肝的疗效

Outcome of Polyethylene glycol interferon alpha 2a injection combined Ribavirin in treatment of chronic hepatitis C

目的通过聚乙二醇干扰素α-2a注射液联合利巴韦林治疗慢性丙型肝炎(简称慢性丙肝),探讨分析联合治疗的临床疗效和安全性。方法将70例慢性丙肝患者分为对照组和研究组,对照组进行普通干扰素联合利巴韦林治疗,研究组给予聚乙二醇干扰素α-2a注射液联合利巴韦林治疗,总疗程时间为48周,通过对比血清HCV-RNA结果,评价聚乙二醇干扰素α-2a注射液联合利巴韦林治疗慢性丙肝的应用价值。结果两组之间经治疗后的病情差异具有统计学意义(P<0.05),但不良反应差异并无统计学意义。结论针对慢性丙肝患者,聚乙二醇干扰素α-2a注射液联合利巴韦林治疗效果明显,值得临床推广。

Objective To explore the clinical efficacy and safety of Polyethylene glycol（PEG）interferon alpha 2ainjection plus Ribavirin in treatment of chronic hepatitis C. Methods Seventy patients with chronic hepatitis C were randomly divided into a control group and a study group,patients in the control group received common interferon plus Ribavirin,but patients in the study group were given polyethylene glycol interferon alpha 2ainjection plus Ribavirin,for a total cycle of 48 weeks.The comparison of serum HCV- RNA measurements between the two groups was performed for assessment the applied value of ethylene glycol interferon alpha 2ainjection plus Ribavirinchronic in treating chronic hepatitis C. Results The comparison of disease status between the two groups showed statistically significant difference（P〈0.05）,but the comparison of adverse reaction yielded no statistical difference. Conclusion In view of the patients with chronic hepatitis C,therapeutic effect of polyethylene glycol（PEG）interferon alpha 2ainjection plus Ribavirin is satisfactory,which can be worthy of clinical popularization.